Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20(+) non-Hodgkin's lymphoma

Medical Oncology

Volumn 27, Issue 3, 2010, Pages 743-746

  Dzietczenia, Justyna ^a   Wróbel, Tomasz ^a   Mazur, Grzegorz ^a   Porȩba, Rafał ^a   Jaźwiec, Bozena ^a   Kuliczkowski, Kazimierz ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Complement; Complement mediated cytotoxicity; Complement regulatory proteins; Lymphoma; Rituximab

Indexed keywords

CD20 ANTIGEN; CD59 ANTIGEN; CYCLOPHOSPHAMIDE; DECAY ACCELERATING FACTOR; DOXORUBICIN; MEMBRANE COFACTOR PROTEIN; PREDNISONE; REGULATOR PROTEIN; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MALE; NONHODGKIN LYMPHOMA; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD46; ANTIGENS, CD55; ANTIGENS, CD59; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMPLEMENT ACTIVATION; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG MONITORING; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; TUMOR BURDEN; VINCRISTINE;

EID: 77956941691     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9278-9     Document Type: Article

References (12)

1. J Golay, et al. 2000 Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis Blood 95 3900 3908 1:CAS:528:DC%2BD3cXktFCht7o%3D 10845926
2. DR Andersen A Grillo-Lopez C Varnas KS Chambers N Hanna 1997 Targeted anti-cancer therapy using rituximab, a chimeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma Biochem Soc Trans 25 705 708
3. P Macor F Tedesco 2007 Complement as effector system in cancer immunotherapy Immunol Lett 111 6 13 10.1016/j.imlet.2007.04.014 1:CAS:528:DC%2BD2sXnsFKmtrc%3D 17572509 (Pubitemid 47017475)
4. RC Riley-Vargas DB Gill C Kemper MK Liszewski JP Atkinson 2004 CD46: expanding beyond complement regulation Trends Immunol 25 496 503 10.1016/j.it.2004.07.004 1:CAS:528:DC%2BD2cXmvFWmu7g%3D 15324743 (Pubitemid 39490257)
5. F Ziller, et al. 2005 Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59 Eur J Immunol 35 2175 2183 10.1002/eji.200425920 1:CAS:528:DC%2BD2MXmvVeju7k%3D 15971270 (Pubitemid 41015056)
6. K Jurianz, et al. 1999 Complement resistance of tumor cells: basal and induced mechanism Mol Immunol 36 929 939 10.1016/S0161-5890(99)00115-7 1:CAS:528:DC%2BD3cXht1Gnur8%3D 10698347 (Pubitemid 30100845)
7. LG Durrant, et al. 2003 Enhanced expression of the complement regulatory proteins predicts a poor prognosis in colorectal cancer patients Cancer Immunol Immunother 52 638 642 10.1007/s00262-003-0402-y 1:STN:280:DC%2BD3svkslSgtA%3D%3D 12811528 (Pubitemid 37268197)
8. VT Blok, et al. 2000 A possible role of CD46 for the protection in vivo of human renal tumor cells from complement-mediated damage Lab Invest 80 335 344 1:CAS:528:DC%2BD3cXis1egs7g%3D 10744069
9. J Golay, et al. 2001 CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59 Blood 98 3383 3389 10.1182/blood.V98.12.3383 1:CAS:528:DC%2BD3MXovVSgsb8%3D 11719378
10. D Guc H Canpmar C Kucukasu E Kansu 2000 Expression of complement regulatory proteins CR1, DAF, MCP and CD59 in haematological malignancies Eur J Haematol 64 3 9 10.1034/j.1600-0609.2000.80097.x 1:CAS:528:DC%2BD3cXhtl2htLs%3D 10680700 (Pubitemid 30055538)
11. WK Weng R Levy 2001 Expression of complement inhibitors CD46, CD55 and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma Blood 98 1352 1357 10.1182/blood.V98.5.1352 1:CAS:528:DC%2BD3MXmvFGjtrY%3D 11520782
12. K Takei T Yamazaki U Sawada H Ishizuka S Aizawa 2006 Analysis of changes in CD20, CD55 and CD59 expression on established rituximab-resistant B-lymphoma cell lines Leuk Res 30 625 631 10.1016/j.leukres.2005.09.008 1:CAS:528:DC%2BD28Xit1Cltrg%3D 16289746 (Pubitemid 43374591)